Retatrutide
An investigational triple agonist of GLP-1, GIP, and glucagon receptors producing some of the largest weight-loss results recorded in trials.
Overview
Retatrutide is the first peptide to simultaneously activate three metabolic receptors — GLP-1, GIP, and glucagon. Often referred to as a 'next-generation Ozempic,' it has produced exceptional weight-loss outcomes in early trials and is widely considered the leading edge of incretin-based therapy.
Benefits
- Targets appetite, insulin response, and energy expenditure
- Among the highest weight-loss percentages reported in trials
- Glucagon arm may add a metabolic boost beyond GLP-1/GIP alone
- Once-weekly administration
Mechanism of Action
Retatrutide binds GLP-1, GIP, and glucagon receptors. The GLP-1 and GIP arms suppress appetite, slow gastric emptying, and improve insulin response, while the glucagon arm increases lipolysis and energy expenditure — combining the strengths of incretin therapy with metabolic activation.
Dosage (informational only)
- Typical range
- 1–12 mg per week (trial range)
- Frequency
- Weekly subcutaneous administration
Currently investigational. Dosing is titrated upward over weeks to reduce GI side effects. Not approved for general use.
Side Effects
- Nausea and vomiting
- Diarrhea or constipation
- Decreased appetite
- Possible heart-rate elevation
Related peptides
A long-acting GLP-1 receptor agonist studied for its effects on appetite, satiety, and glucose regulation.
A dual GIP and GLP-1 receptor agonist with strong effects on appetite, glucose handling, and body composition.
A small-molecule oral GLP-1 receptor agonist studied as a needle-free alternative to injectable incretin therapy.